Siemens Healthineers AG SHL.DE · XETRA
41.90 € +0.46% (+0.19 €)
Summary
59 / 100 · Bulios Score
What speaks for it
- It passes 9 of the 9 points of the Piotroski financial health test.
- It has been profitable 6 years in a row.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue grew by only 2.5% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 21.1 EUR for 1 EUR of yearly profit. Over the last five years it was 30.3 EUR on average.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 10% a year over 5 years. Over the last 3 years it grew by 2.5% a year. For the next fiscal year analysts expect revenue to grow by 0.8%. Earnings per share grew by 1.8% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 EUR of revenue goes
- Cost of sales 61 EUR
- Research and development 8.4 EUR
- Sales and administration 16 EUR
- Taxes and other 5.3 EUR
- Net profit 9.6 EUR
Net profit, industry median (Medical - Devices) 6.9 EUR
Out of every 100 EUR of revenue, 9.6 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 2.40%
- Paid out of profit
- 51%
You receive 1.00 € per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 1
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detail